Likely first-line therapy for a highly prevalent menstrual disorder.
A new way to treat painful, heavy menstrual periods. Three US patents (10,251,836, 10,709,679, and 11,351,132)
Enhanta is a novel, proprietary oral drug combination of an NSAID and a low-dose antifibrinolytic (tranexamic acid) that combines two popular medications in the safest and most efficacious way.
Two valuable formulations:
Prescription-strength (Rx) - for women clinically diagnosed with dysmenorrhea (painful menstrual periods) and/or menorrhagia (excessive menstrual blood loss);
Over-the-counter (OTC) - for women perceiving their menstrual periods as painful and heavy (no diagnosis).
Phase IIb-ready, could be a Phase III asset (to be confirmed by the FDA).